FGF2 De-differentiation of Adult Fibroblasts for Cell Longevity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current de-differentiation protocols for achieving pluripotent cells from adult connective tissue are inefficient and limited, with primary cells having a short in vitro lifespan, making extended genetic studies and clinical applications challenging.
Innovation Solution
The use of basic fibroblast growth factor (FGF2) combined with low oxygen culture conditions and an extracellular matrix to de-differentiate adult fibroblasts, increasing their longevity and allowing for the expansion of pluripotent cells, which can be used in therapeutic applications such as tissue repair and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If primary fibroblasts are used for culturing, then the cells can be obtained easily from adult connective tissue, but the in vitro lifespan is limited making extended studies impossible
Solution Approach 1:
The patent applies parameter changes by modifying the culture conditions (adding basic FGF2 growth factor, changing oxygen levels, adjusting medium composition) to transform the biological properties of fibroblasts. These parameter changes in the culture environment enable the cells to overcome their natural lifespan limitation and achieve extended in vitro proliferation while maintaining their differentiated phenotype, thus resolving the contradiction between ease of acquisition and limited lifespan
2Duration of action of moving object
If de-differentiation protocols are used to achieve pluripotent cells, then cell longevity may be increased, but the protocols are inefficient and limited
Solution Approach 1:
The patent extracts and isolates the specific growth factor basic FGF2 as the key component responsible for extending fibroblast lifespan. By taking out this specific factor from complex de-differentiation protocols, the invention achieves efficient cell longevity extension without requiring full de-differentiation to pluripotent states, thus improving productivity while maintaining the beneficial effect on cell lifespan
3Productivity
If growth factors are used to increase proliferation rates, then cell expansion may be achieved, but success has been limited with current protocols
Solution Approach 1:
The patent employs feedback mechanisms by using basic FGF2, which acts as an autocrine growth factor that stimulates fibroblast proliferation through feedback loops. The growth factor binds to receptors on fibroblast surfaces, triggering intracellular signaling pathways that regulate cell cycle progression and proliferation, thereby achieving reliable and sustained cell expansion with high protocol success rate
Data Source
AI summary
De-differentiation protocols are described herein for generating progenitor cells from adult connective tissue, in particular adult human fibroblasts. The de-differentiation protocols described herein comprise culturing the differentiated cells with an amount of FGF2 to de-differentiate the cells. These de-differentiated cells may then be cultured and used for experimentation, amplification and clinical applications. The clinical applications include the use of the cells for tissue and cell based therapies.